Table 1.

Patients’ characteristics

	N	%	Total extracellular DNA ng/mL median	p-value	Extracellular nuclear DNA ge/mL median	p-value	Extracellular mitochondrial DNA ge/mL median	p-value
All patients	67	100.0	8.3		2266		16,526	NA
Surgical Debulking
Optimal	35	52.2	8.26	0.35	1944	0.13	11,422	0.09
Suboptimal	32	47.8	8.94		2584		20,297
Histology
Serous	53	79.1	9	0.31	2422	0.63	16,526	0.70
Other	14	20.9	6.16		1919		13,117
Grade
1 and 2	14	20.9	7.63	0.47	2083	0.49	16,470	0.90
3	41	61.2	8.32		2266		15,646
Unknown	12	17.9
Stage
1	12	17.9	5.3	0.58	1862	0.45	8604	0.16
2	7	10.4	8.26		2422		16,526
3	43	64.2	9		2455		17,575
4	5	7.5	9.7		1736		16,413
Stage
1	12	17.9	5.3	0.19	1862	0.18	8604	0.03
2 to 4	55	82.1	9		2438		16,984
		0.0
Chemotherapy
paclitaxel+carboplatin	25	37.3	6.26	0.21	1893	0.19	14,314	0.76
paclitaxel+carboplatin+bevacizumab	42	62.7	9.17		2447		16,755